Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy
- PMID: 6426577
- PMCID: PMC1441018
- DOI: 10.1136/bmj.288.6428.1405
Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy
Abstract
Some relations between metastatic bone disease and calcium homoeostasis were determined in a consecutive series of 81 patients with solid malignant tumours attending for radionuclide bone scans. Biochemical evaluation showed that bone resorption from metastatic disease was generally not enough to account for hypercalcaemia. While skeletal metastases were present in about half of the patients who developed hypercalcaemia, biochemical indices of bone resorption in these subjects were greatly increased and disproportionate to the extent of metastatic disease detected by the bone scans. Furthermore, a reduced renal phosphate threshold and increased tubular calcium reabsorption were generally observed in hypercalcaemic patients when compared with their normocalcaemic counterparts. These findings suggest that in most cases malignancy associated hypercalcaemia may be caused by the release of a humoral factor by tumour tissue which exhibits "parathyroid-hormone-like" activity with regard to bone resorption, renal phosphate threshold, and renal calcium handling. It may be postulated that this putative humoral mediator predisposes to hypercalcaemia both by stimulating generalised osteolysis and in most cases also by impairing the renal excretion of the resultant increase in filtered calcium load. While hypercalcaemia may arise as a result of metastatic bone disease alone, these data indicate that this may be the exception rather than the rule. Hence the term "metastatic hypercalcaemia" should probably be reserved for patients with extensive skeletal tumour disease in whom biochemical evaluation fails to yield evidence of an underlying humorally mediated cause.
Similar articles
-
Mechanism of malignant hypercalcaemia in carcinoma of the breast.Br Med J (Clin Res Ed). 1985 Sep 21;291(6498):776-9. doi: 10.1136/bmj.291.6498.776. Br Med J (Clin Res Ed). 1985. PMID: 3929936 Free PMC article.
-
Hypercalcaemia and metastatic bone disease: is there a causal link?Lancet. 1982 Oct 23;2(8304):903-5. doi: 10.1016/s0140-6736(82)90868-6. Lancet. 1982. PMID: 6126753
-
Humoral hypercalcaemia of malignancy: metabolic and histomorphometric studies during surgical management of the primary tumour.Q J Med. 1986 Mar;58(227):325-35. Q J Med. 1986. PMID: 3016790
-
Hypercalcaemia of malignancy.Cancer Metastasis Rev. 1989 Jun;8(1):23-52. doi: 10.1007/BF00047056. Cancer Metastasis Rev. 1989. PMID: 2667784 Review.
-
Pathogenesis of hypercalcaemia of malignancy.Clin Endocrinol (Oxf). 1985 Dec;23(6):705-14. doi: 10.1111/j.1365-2265.1985.tb01132.x. Clin Endocrinol (Oxf). 1985. PMID: 3006948 Review.
Cited by
-
Hypercalcaemia: historical perspectives and present management.Support Care Cancer. 1993 Jan;1(1):19-25. doi: 10.1007/BF00326635. Support Care Cancer. 1993. PMID: 8143097 Review.
-
The management of hypercalcemia of malignancy.Support Care Cancer. 1995 Mar;3(2):123-9. doi: 10.1007/BF00365852. Support Care Cancer. 1995. PMID: 7773580 Review.
-
3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.Br J Cancer. 1987 Oct;56(4):465-9. doi: 10.1038/bjc.1987.225. Br J Cancer. 1987. PMID: 3689664 Free PMC article.
-
Hypercalcaemia and hypocalcaemia: finding the balance.Support Care Cancer. 2017 May;25(5):1639-1649. doi: 10.1007/s00520-016-3543-1. Epub 2017 Jan 12. Support Care Cancer. 2017. PMID: 28078478 Free PMC article. Review.
-
Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift.Endocr Connect. 2021 Jan;10(1):R13-R24. doi: 10.1530/EC-20-0487. Endocr Connect. 2021. PMID: 33289687 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical